1H21 Half Year Results
Filed with ASX · · 6 pages · English
Melbourne, Australia, 26 February 2021:Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), adiversified Genomics and AI driven preventative health business is pleased to Melbourne, Australia, [21] October 2020:provide the half year results for the period ending 31 December 2020.Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- Genetic Technologies US$6.56 Million Capital Raising
- Genetic Technologies appoints Simon Morriss as CEO
- GTG Secures US and ANZ Distribution Rights for PREDICTIX
- GTG Announces US$5.1 Million Capital Raising
- Response to ASX Early Release of Information Query
Later from Genetic Technologies
- Pause in Trading
- GTG signs 3-year US licence agreement for COVID risk test
- COVID- 19 Risk Test Approved for Commercial Release
- GTG COVID-19 Risk Test launched in USA
- US Patent Office Grants Foundational Pharmacogenomic Patent
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies